Page 4 - Immunic Inc Nasdaq News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic inc nasdaq. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Nasdaq Today - Breaking & Trending Today

Innovis Asset Management LLC Purchases Shares of 80,773 Immunic, Inc. (NASDAQ:IMUX)

Innovis Asset Management LLC purchased a new stake in Immunic, Inc. (NASDAQ:IMUX – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 80,773 shares of the company’s stock, valued at approximately $120,000. Innovis Asset Management LLC owned 0.18% […] ....

United States , Vivo Capital , Immunic Company Profile , Innovis Asset Management , America Corp , Exchange Commission , Morgan Stanley , Immunic Inc , Artal Group , Free Report , Asset Management , Stock Down , Visit Holdingschannel , Immunic Daily , Nasdaq Imux , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Immunic (NASDAQ:IMUX) Rating Reiterated by Wedbush

Wedbush restated their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note published on Friday, RTT News reports. They currently have a $5.00 price target on the stock. Separately, StockNews.com started coverage on Immunic in a research note on Thursday, May 18th. They issued a sell rating on the stock. […] ....

Virtu Financial , Innovis Asset Management , Vontobel Holding Ltd , Artal Group , Gratus Capital , Immunic Inc , Free Report , Get Free Report , Asset Management , Vontobel Holding , Immunic Daily , Nasdaq Imux , Reiterated Rating ,

Immunic (NASDAQ:IMUX) Receives Outperform Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note published on Friday morning, RTT News reports. They currently have a $5.00 price target on the stock. Separately, StockNews.com initiated coverage on Immunic in a research report on Thursday, May 18th. They set a sell rating on the […] ....

Vontobel Holding Ltd , Immunic Inc , Immunic Company Profile , Charles Schwab Investment Management Inc , Jpmorgan Chase Co , Marshall Wace , Free Report , Stock Down , Get Free Report , Schwab Investment Management , Immunic Daily , Nasdaq Imux , Reiterated Rating ,

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective. ....

Paula Schwartz , Daniel Vitt , Jessica Breu , Edna Kaplan , Vincent Ossipow , Richard Rudick , Development Rd Expenses , Rx Communications Group , Exchange Commission , Prnewswire Immunic Inc , Immunic Inc , Preclinical Data Published , Potent Nurr , Reinforcing Neuroprotective Potential , Multiple Sclerosis , Positive Results From Phase , Clinical Trial , Celiac Disease Provide Proof Of Concept , New Therapeutic Approach , Treat Gastrointestinal Diseases , Promoting Regeneration , Bowel Architecture , Interim Results From Phase , Vidofludimus Calcium , Progressive Multiple Sclerosis Expected , Cash Equivalents ,

Immunic to Participate in Investor and Scientific Conferences in August

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for. ....

New York , United States , Daniel Vitt , Evelyn Peelen , Paula Schwartz , Jessica Breu , Edna Kaplan , Exchange Commission , Immunic Inc , International Congress , Prnewswire Immunic Inc , Rx Communications Group , Pacgrow Healthcare , Chief Executive Officer , Senior Manager Translational Pharmacology , Vidofludimus Calcium , Orally Available , Multiple Sclerosis , Potently Activates , Private Securities Litigation Reform Act , Annual Report , Investor Relations ,